Key facts
- This page summarizes David Zaccardelli's Form 4 filing for Vor Biopharma Inc. (VOR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jul 2026, 16:01.
David Zaccardelli - 07 Jul 2026 Form 4 Insider Report for Vor Biopharma Inc. (VOR)
- Reporting relationship
- Director
- Issuer ticker
- VOR
- Reported as of
- 07 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jul 2026, 16:01:02 UTC
- Prior SEC filing
- 07 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adi Osovsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Zaccardelli filed Form 4 for Vor Biopharma Inc. (VOR) on 09 Jul 2026.
Change
- Previous filing in this sequence was filed on 07 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001627642
Primary reporting owner
ZACCARDELLI DAVID
- Relationship
- Director
- Address
- 500 BOYLSTON STREET, SUITE 1350, BOSTON
- Signature
- /s/ Adi Osovsky, Attorney-in-Fact
- Signature date
- 09 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VOR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +42,658
- Change %
- Price
- $0.000000*
- Shares after
- 42,658
- Date
- 07 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,658
- Exercise price
- $20.10
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on August 7, 2026, in each case subject to the Reporting Person's continued service as of each such date.